Literature DB >> 30670418

Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Rodrigo E Mendes1, Susanne Paukner2, Timothy B Doyle3, Steven P Gelone4, Robert K Flamm3, Helio S Sader3.   

Abstract

This study investigated the molecular mechanisms possibly associated with non-wild-type MICs for lefamulin among staphylococci and streptococci included in the lefamulin surveillance program from 2015 to 2016. A total of 2,919 Staphylococcus aureus, 276 coagulase-negative staphylococci (CoNS), 3,923 Streptococcus pneumoniae, 389 β-hemolytic, and 178 viridans group streptococci isolates were included in the surveillance studies. Eleven (0.3% of all S. aureus) S. aureus isolates with lefamulin MICs above the staphylococcal epidemiological cutoff (ECOFF) value (>0.25 μg/ml) were selected for this study. Eight (72.7%) S. aureus (lefamulin MIC, 0.5 to 4 μg/ml) isolates carried vga(A or E), one isolate (MIC, 32 μg/ml) carried lsa(E), one isolate (MIC, 16 μg/ml) had an alteration in L4, and one strain (MIC, 0.5 μg/ml) did not carry any of the investigated resistance mechanisms. A total of 14 (5.1% of all CoNS) CoNS isolates had lefamulin MICs (0.5 to >32 μg/ml) above the ECOFF. Similar to S. aureus, 8 (57.1%) CoNS (lefamulin MIC, 1 to 8 μg/ml) isolates carried vga(A or B), while 2 isolates (MIC, 4 to 32 μg/ml) carried cfr High genetic diversity was observed among staphylococci, although 3 S. aureus isolates belonged to sequence type 398 (ST398). Among the 3 Streptococcus agalactiae and 3 viridans group streptococci (0.1% of all streptococci surveyed) isolates selected for additional characterization, all but 1 isolate carried lsa(E). This study documents a low occurrence of surveillance isolates exhibiting a non-wild-type MIC for lefamulin, and among these isolates, vga and lsa(E) prevailed in staphylococci and streptococci, respectively.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  BC-3781; lsa(E); pleuromutilins; vga(A)

Year:  2019        PMID: 30670418      PMCID: PMC6437497          DOI: 10.1128/AAC.02158-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Small plasmids carrying vga(A) or vga(C) genes mediate resistance to lincosamides, pleuromutilins and streptogramin A antibiotics in methicillin-resistant Staphylococcus aureus ST398 from swine.

Authors:  Kristina Kadlec; Constança F Pomba; Natacha Couto; Stefan Schwarz
Journal:  J Antimicrob Chemother       Date:  2010-09-28       Impact factor: 5.790

3.  Characterization of sal(A), a novel gene responsible for lincosamide and streptogramin A resistance in Staphylococcus sciuri.

Authors:  Chloé Hot; Nicolas Berthet; Olivier Chesneau
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

4.  Incidence, management and outcomes of the first cfr-mediated linezolid-resistant Staphylococcus epidermidis outbreak in a tertiary referral centre in the Republic of Ireland.

Authors:  C O'Connor; J Powell; C Finnegan; A O'Gorman; S Barrett; K L Hopkins; B Pichon; R Hill; L Power; N Woodford; J C Coffey; A Kearns; N H O'Connell; C P Dunne
Journal:  J Hosp Infect       Date:  2015-01-13       Impact factor: 3.926

5.  Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.

Authors:  Zohar Eyal; Donna Matzov; Miri Krupkin; Itai Wekselman; Susanne Paukner; Ella Zimmerman; Haim Rozenberg; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-13       Impact factor: 11.205

6.  In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae.

Authors:  Susanne Jacobsson; Susanne Paukner; Daniel Golparian; Jörgen S Jensen; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Jennifer M Streit; Patricia A Hogan; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.

Authors:  Daniel R Gentry; Stephen F Rittenhouse; Lynn McCloskey; David J Holmes
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

Review 9.  Mobile lincosamide resistance genes in staphylococci.

Authors:  Andrea T Feßler; Yang Wang; Congming Wu; Stefan Schwarz
Journal:  Plasmid       Date:  2018-06-19       Impact factor: 3.466

10.  Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center.

Authors:  Keith Miller; Colin J Dunsmore; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

View more
  11 in total

Review 1.  Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.

Authors:  Young Ran Lee; Katy Louise Jacobs
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 2.  Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition.

Authors:  Romney Humphries; April M Bobenchik; Janet A Hindler; Audrey N Schuetz
Journal:  J Clin Microbiol       Date:  2021-09-22       Impact factor: 5.948

Review 3.  Clinical Utility of Lefamulin: If Not Now, When?

Authors:  Nicholas J Mercuro; Michael P Veve
Journal:  Curr Infect Dis Rep       Date:  2020-07-09       Impact factor: 3.725

4.  In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017-2019.

Authors:  Shi Wu; Yonggui Zheng; Yan Guo; Dandan Yin; Demei Zhu; Fupin Hu
Journal:  Front Microbiol       Date:  2020-09-16       Impact factor: 5.640

Review 5.  Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents.

Authors:  Richard R Watkins; Marisa Holubar; Michael Z David
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

6.  MIC Values of Iclaprim and Lefamulin against Mycobacterium abscessus Complex.

Authors:  Ka Lip Chew; Sophie Octavia; Siang Fei Yeoh; Jeanette W P Teo
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

Review 7.  Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Authors:  Yang Liu; Yan Zhang; Wanyu Zhao; Xiaolei Liu; Fengjuan Hu; Birong Dong
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810

Review 8.  The Impact of Selected Bacterial Sexually Transmitted Diseases on Pregnancy and Female Fertility.

Authors:  Katarzyna Smolarczyk; Beata Mlynarczyk-Bonikowska; Ewa Rudnicka; Dariusz Szukiewicz; Blazej Meczekalski; Roman Smolarczyk; Wojciech Pieta
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

9.  Sal-type ABC-F proteins: intrinsic and common mediators of pleuromutilin resistance by target protection in staphylococci.

Authors:  Merianne Mohamad; David Nicholson; Chayan Kumar Saha; Vasili Hauryliuk; Thomas A Edwards; Gemma C Atkinson; Neil A Ranson; Alex J O'Neill
Journal:  Nucleic Acids Res       Date:  2022-02-28       Impact factor: 16.971

10.  Structural basis of ABCF-mediated resistance to pleuromutilin, lincosamide, and streptogramin A antibiotics in Gram-positive pathogens.

Authors:  Caillan Crowe-McAuliffe; Victoriia Murina; Kathryn Jane Turnbull; Marje Kasari; Merianne Mohamad; Christine Polte; Hiraku Takada; Karolis Vaitkevicius; Jörgen Johansson; Zoya Ignatova; Gemma C Atkinson; Alex J O'Neill; Vasili Hauryliuk; Daniel N Wilson
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.